PTPRC and melanoma: To test this notion ex vivo, TILs (tumor infiltrating lymphocytes – CD45+) were extracted from YUMM2.1 melanoma tumors (n = 5) that were treated for 14 days with either IgG or anti-N1 (10 mg/Kg, every other day).